DAMORA THERAPEUTICS, INC. Operating Cash Flow
DAMORA THERAPEUTICS, INC. (DMRA) reported Operating Cash Flow of -$42.47 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-10
- DAMORA THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$21.87M.
- DAMORA THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$20.60M.
- DAMORA THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was $566.00K.
- DAMORA THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$2.62M.
- DAMORA THERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2025 was -$6.73M.
- DAMORA THERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2024 was -$18.62M.
- DAMORA THERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2023 was -$36.91M.
- DAMORA THERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2022 was -$42.93M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$21.87M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | -$42.47M 10-Q · filed 2026-08-10 | -$41.90M derived: sum of 3 quarters · filed 2026-08-10 | -$44.52M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | -$20.60M 10-Q · filed 2026-05-12 | -$20.03M derived: sum of 2 quarters · filed 2026-05-12 | -$22.65M derived: sum of 3 quarters · filed 2026-05-12 | -$24.89M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $566.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | -$2.05M derived: sum of 2 quarters · filed 2026-03-19 | -$4.29M derived: sum of 3 quarters · filed 2026-08-10 | -$6.73M 10-K · filed 2026-03-19 |
| 2025-09-30 | -$2.62M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$4.85M derived: sum of 2 quarters · filed 2026-08-10 | -$7.29M 10-Q · filed 2025-11-06 | -$12.23M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | -$2.24M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | -$4.68M 10-Q · filed 2026-08-10 | -$9.61M derived: sum of 3 quarters · filed 2026-08-10 | -$13.26M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | -$2.44M 10-Q · filed 2026-05-12 | -$7.38M derived: sum of 2 quarters · filed 2026-05-12 | -$11.03M derived: sum of 3 quarters · filed 2026-05-12 | -$15.13M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | -$4.94M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | -$8.59M derived: sum of 2 quarters · filed 2026-03-19 | -$12.69M derived: sum of 3 quarters · filed 2026-03-19 | -$18.62M 10-K · filed 2026-03-19 |
| 2024-09-30 | -$3.65M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$7.75M derived: sum of 2 quarters · filed 2025-11-06 | -$13.69M 10-Q · filed 2025-11-06 | -$25.16M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | -$4.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | -$10.04M 10-Q · filed 2025-08-05 | -$21.51M derived: sum of 3 quarters · filed 2025-08-05 | -$29.96M derived: sum of 4 quarters · filed 2025-08-05 |
| 2024-03-31 | -$5.94M 10-Q · filed 2025-05-08 | -$17.41M derived: sum of 2 quarters · filed 2025-05-08 | -$25.86M derived: sum of 3 quarters · filed 2025-05-08 | -$33.71M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | -$11.47M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-19 | -$19.93M derived: sum of 2 quarters · filed 2025-03-19 | -$27.78M derived: sum of 3 quarters · filed 2025-03-19 | -$36.91M 10-K · filed 2025-03-19 |
| 2023-09-30 | -$8.45M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-01 | -$16.30M derived: sum of 2 quarters · filed 2024-11-01 | -$25.44M 10-Q · filed 2024-11-01 | -$36.88M derived: sum of 4 quarters · filed 2024-11-01 |
| 2023-06-30 | -$7.85M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | -$16.98M 10-Q · filed 2024-08-12 | -$28.43M derived: sum of 3 quarters · filed 2024-08-12 | -$38.28M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | -$9.13M 10-Q · filed 2024-04-29 | -$20.58M derived: sum of 2 quarters · filed 2024-04-29 | -$30.43M derived: sum of 3 quarters · filed 2024-04-29 | -$45.27M derived: sum of 4 quarters · filed 2024-04-29 |
| 2022-12-31 | -$11.45M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-08 | -$21.30M derived: sum of 2 quarters · filed 2024-03-08 | -$36.13M derived: sum of 3 quarters · filed 2024-03-08 | -$42.93M 10-K · filed 2024-03-08 |
| 2022-09-30 | -$9.85M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | -$24.69M derived: sum of 2 quarters · filed 2023-11-06 | -$31.48M 10-Q · filed 2023-11-06 | -$49.31M derived: sum of 4 quarters · filed 2023-11-06 |
| 2022-06-30 | -$14.84M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-07-31 | -$21.64M 10-Q · filed 2023-07-31 | -$39.47M derived: sum of 3 quarters · filed 2023-07-31 | -$48.63M derived: sum of 4 quarters · filed 2023-07-31 |
| 2022-03-31 | -$6.80M 10-Q · filed 2023-04-28 | -$24.63M derived: sum of 2 quarters · filed 2023-04-28 | -$33.78M derived: sum of 3 quarters · filed 2023-04-28 | -$44.95M derived: sum of 4 quarters · filed 2023-04-28 |
| 2021-12-31 | -$17.83M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | -$26.99M derived: sum of 2 quarters · filed 2023-03-09 | -$38.16M derived: sum of 3 quarters · filed 2023-03-09 | -$52.31M 10-K · filed 2023-03-09 |
| 2021-09-30 | -$9.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | -$20.33M derived: sum of 2 quarters · filed 2022-11-08 | -$34.48M 10-Q · filed 2022-11-08 | -$49.00M derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | -$11.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-07-29 | -$25.32M 10-Q · filed 2022-07-29 | -$39.84M derived: sum of 3 quarters · filed 2022-07-29 | -$48.41M derived: sum of 4 quarters · filed 2022-07-29 |
| 2021-03-31 | -$14.15M 10-Q · filed 2022-04-29 | -$28.67M derived: sum of 2 quarters · filed 2022-04-29 | -$37.24M derived: sum of 3 quarters · filed 2022-04-29 | -$44.38M derived: sum of 4 quarters · filed 2022-04-29 |
| 2020-12-31 | -$14.52M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-17 | -$23.09M derived: sum of 2 quarters · filed 2022-02-17 | -$30.23M derived: sum of 3 quarters · filed 2022-02-17 | -$38.20M 10-K · filed 2022-02-17 |
| 2020-09-30 | -$8.58M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | -$15.71M derived: sum of 2 quarters · filed 2021-11-04 | -$23.69M 10-Q · filed 2021-11-04 | -$28.94M derived: sum of 4 quarters · filed 2021-11-04 |
| 2020-06-30 | -$7.13M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | -$15.11M 10-Q · filed 2021-08-05 | -$20.36M derived: sum of 3 quarters · filed 2021-08-05 | |
| 2020-03-31 | -$7.98M 10-Q · filed 2021-05-04 | -$13.23M derived: sum of 2 quarters · filed 2021-05-04 | ||
| 2019-12-31 | -$5.25M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-29 | -$19.33M 10-K · filed 2021-03-29 | ||
| 2019-09-30 | -$14.07M 10-Q · filed 2020-12-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |